PharmaDiversityJobBoard-Diversity Job Board connecting diversity & minority job seekers with Pharmaceutical jobs. Amerisource Bergen Jobs (ABC)
  Home  |  Login  |  Job Seeker Register  |  Employer Register    You're not logged in!
Translate:

AstraZeneca Pharmaceuticals Jobs

 
Click links to read Current News for this Featured Employer    FluMist® Begins Shipping for 2010-2011 Influenza Season | AstraZeneca and Grace Hill Neighborhood Health Centers, Inc. Provide Medicines to Missouri's Uninsured | Silence Therapeutics and AstraZeneca Extend siRNA Development Collaboration | Brazil's Non-Small-Cell Lung Cancer Drug Market will Reach $240 Million by 2014 | ARIMIDEX® (anastrozole) Tablets Savings Card Provides Instant Savings to Eligible Patients | CRESTOR® Patent Upheld By US Court | Ron Laufer named Senior Managing Director of MedImmune Ventures | First Phase III Trial With Definitive Results in Advanced Medullary Thyroid Cancer Shows Statistically Significant Extension of Progression Free Survival for Patients | FDA Advisory Committee Reviews MedImmune's Motavizumab | AstraZeneca Recognized for Eco-Leadership | AstraZeneca to Support Drug-Induced Liver Injury Network at the National Institutes of Health | The Opportunity Center and AstraZeneca Partner To Educate Local Students With Disabilities | AstraZeneca Donates $1 Million for Christiana Care Health System's Wilmington Hospital Project | AstraZeneca and Carolina Family Health Centers, Inc. Provide Medicines to North Carolina's Uninsured | MedImmune to Present Five Abstracts on RSV at Pediatric Academic Societies Annual Meeting | TB Alliance and AstraZeneca Form Research Collaboration to Fight Tuberculosis | AstraZeneca Traveling Patient Health Exhibit Continues to Help Americans Understand and Manage Bipolar Depression | CRESTOR(TM) Gains New EU Indication to Prevent Major Cardiovascular Events in High Risk Patients | /C O R R E C T I O N -- Sheller, P.C./ | Pharmaceutical Giant AstraZeneca to Pay $520 Million for Off-Label Drug Marketing | Silence Therapeutics and AstraZeneca Extend siRNA Delivery Collaboration | AstraZeneca HealthCare Foundation Announces Its Newest Program - Connections for Cardiovascular Health(SM) | MedImmune to Present 10 Abstracts on Influenza at 44th National Immunization Conference | AstraZeneca Recognizes Employee Volunteerism | AstraZeneca/Targacept's TC-5214 Will Become Decision Resources' Proprietary Clinical Gold Standard In 2013 Through 2018 For Treatment Resistant Depression | MedImmune Showcases Commitment to Cancer Research at Annual Meeting of the American Association for Cancer Research | Reportlinker Adds AstraZeneca plc: PharmaVitae Profile | AstraZeneca and Abbott Receive FDA Complete Response Letter on CERTRIAD(TM) New Drug Application | Palatin Technologies, Inc. Receives $2.5 Million from AstraZeneca | AstraZeneca Comments on FDA Joint Advisory Committee Meeting on Post-Marketing Safety Studies for the Use of LABAs in Asthma | Rigel to Host Conference Call Today to Discuss Its Partnership With AstraZeneca on Fostamatinib Disodium (R788) | AstraZeneca and Rigel Pharmaceuticals Sign Worldwide License Agreement for Late-Stage Development Product -- Fostamatinib Disodium (R788) -- for the Treatment of Rheumatoid Arthritis (RA) | AstraZeneca Prescription Savings Programs Help More Patients in 2009 | Shire Presents Positive Efficacy and Safety Data for velaglucerase alfa in Treatment of Naive Patients With Type 1 Gaucher Disease | Pivotal Trial Results for Motavizumab Published in Current Issue of 'Pediatrics' | /C O R R E C T I O N -- Decision Resources/ | AstraZeneca and Dako Sign Agreement to Develop Companion Diagnostics for Cancer Treatments | AstraZenenca and CrystalGenomics, Inc. Form Research Collaboration to Develop Novel Anti-Infective Treatments | AstraZeneca Offers Online Enrollment and Additional Improvements to Patient Assistance Program | VentiRx Pharmaceuticals Raises $25 Million in Series A Extension Financing | AstraZeneca and the University of Virginia Sign Strategic Research Collaboration to Develop Novel Treatments for Cardiovascular Disease | AstraZeneca Medicare Part D Patient Assistance Program No Longer Requires Co-Pays | U.S. Court of Appeals Upholds AstraZeneca AWP Settlement | AstraZeneca and the Philadelphia Department of Public Health Provide Free Medicines to Pennsylvania's Uninsured | AstraZeneca Submits US New Drug Application for Ticagrelor (BRILINTA(TM)), an Investigational Antiplatelet Agent | Video: CRESTOR(R) Reduced Risk of Cardiovascular Events in Women by Nearly Half in New Analysis of JUPITER Study Two Additional Sub-population Analyses from JUPITER Also Presented at American Heart Association Annual Meeting | MedImmune Announces Winners of the 4th Respiratory, Immunology and Autoimmunity Research Abstract Competition | Emerging Agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/Astrazeneca/Takeda Will Drive Modest Growth in the MRSA Drug Market Through 2018 Increasing Prevalence of MRSA and Uptake of Emerging Therapies Will Drive Market to Grow to More Than $1 Billion, According to a New Report from Decision Resources | Video: Ticagrelor (BRILINTA(TM)) Demonstrated Greater Efficacy Over Clopidogrel in the Most Urgent Clinical Setting: Patients with ST-Segment Elevation Myocardial Infarction and Planned Percutaneous Coronary Intervention (PCI) Late breaking data from PLATO sub-analysis presented at the American Heart Association Scientific Sessions | American Heart Association Late-Breaking Clinical Trial Report: New Reversible Oral Drug Reduces Cardiac Events in Primary PCI Patients | Dr. Steven M. Paul to Retire from Lilly as Executive Vice President, Science and Technology, President, Lilly Research Laboratories; Dr. Jan M. Lundberg, Executive Vice President, Head of Global Discovery Research, AstraZeneca, Named his Successor | Actress Debi Mazar Talks About her Family's Experience with Bipolar Depression Debi shares her inspirational story as part of campaign to educate people about bipolar disorder | Widespread Generic Erosion of Atypical Antipsychotics Will Cause the Bipolar Disorder Drug Market to Decline By More Than $1 Billion Through 2018 Beginning in 2011, Key Agents from AstraZeneca, Eli Lilly, Pfizer and Bristol-Myers Squibb/Otsuka Will Lose Patent Exclusivity, According to a New Report from Decision Resources | MedImmune to Present Four Abstracts on RSV and Influenza at 47th Annual IDSA Meeting | Four Basics and Some Good Information About Beta-Blocker Treatment for High Blood Pressure | AstraZeneca Partners With Mercy Primary Care Center to Help Michigan Uninsured | MedImmune to Present Data on RSV and Influenza at 2009 American Academy of Pediatrics National Conference & Exhibition | MedImmune Highlights Inflammatory Disease Portfolio at 73rd Annual Meeting of the American College of Rheumatology | Palatin Technologies to Receive $5 Million from AstraZeneca | Appeals Court Denies AstraZeneca in AWP Case, Hagens Berman Announces Ruling Clears Way for National Class Action | Ticagrelor Reduced Cardiovascular Deaths and Heart Attacks in ACS Patients Undergoing Heart Procedures: New Data from PLATO Trial Significant effects shown with no increase in major bleeding compared to clopidogrel in head-to-head trial | AstraZeneca and Nektar Sign Worldwide Agreement for Nektar Drug Development Programmes -- NKTR-118 and NKTR-119 -- to Address Opioid-Induced Constipation | MedImmune Receives U.S. Government Order for Additional 29 Million Doses of Nasal Spray Vaccine for 2009 H1N1 Influenza | Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2009 Results; Teleconference and Webcast to be held on September 8, 2009 | Video: AstraZeneca Traveling Exhibit Helps Americans Understand and Manage Bipolar Depression Interactive exhibit educates and inspires patients and caregivers across the country | MedImmune Advances Three Oncology Programs Into the Clinic | Podcast Alert: Measures For Asthma Success | FluMist(R) Begins Shipping for 2009-2010 Influenza Season Supports CDC's Annual Recommendations for Families to Seek Vaccination for Seasonal Influenza as Soon as Vaccine is Available MedImmune Announces Influenza Vaccination Awareness Campaign with Women's Professional Soccer | AstraZeneca Expands Prescription Savings Program | MAP Pharmaceuticals Announces Termination of Pediatric Asthma Collaboration - Company to Suspend Development of UDB - | Catalyst Biosciences Announces Agreement With MedImmune to Discover and Develop Engineered Protease Therapeutics | MedImmune Funds Study to Help Gain Insights Into Full Burden of RSV Disease Among Premature Infants | Cadient Group Brings Home the Gold and Two Bronze Aster Awards | Palatin Technologies, Inc. Reports Fiscal Year 2009 Third Quarter Results; Teleconference and Webcast to be held on May 15, 2009 | MAP Pharmaceuticals to Present at the Deutsche Bank Securities 34th Annual Health Care Conference | Ingenuity Systems Announces Multi-Year Deal With AstraZeneca | AstraZeneca Submits NDA for Low Dose Aspirin/Esomeprazole Combination Product | New National Online Survey Says Bipolar Depressive Symptoms Have Impact on Day-To-Day Tasks as Well as Social Activities(1) | National Health Experts Launch Bipartisan Coalition to Fight Chronic Disease | FDA Advisory Committee Documents for SEROQUEL XR Available on AstraZeneca Web Site | AstraZeneca Calls on All Americans to Join US AGAINST ATHERO to Fight the Nation's Number One Killer | BioDuro and AstraZeneca Expand Collaboration to Optimize Discovery Research for Respiratory and Inflammation Indications | FDA Approves SYMBICORT(R) for Chronic Obstructive Pulmonary Disease (COPD) | AstraZeneca Announces SEROQUEL XR is Now Available to Treat Bipolar Depression | MAP Pharmaceuticals Announces Phase 3 Study of Unit Dose Budesonide in Children With Asthma Did Not Meet Primary Endpoints | CRESTOR Cuts Risk of Stroke by Nearly Half in JUPITER Study | AstraZeneca Implements Customized Cytel East(R) Software for More Accurate Trial Monitoring and Clinical Data Analysis | Palatin Technologies Announces Receipt of $4.1 Million from AstraZeneca | MAP Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Unit Dose Budesonide Collaboration with AstraZeneca | St. Louis Named Top Asthma Capital for 2009 | AstraZeneca's Drug Will Become the New Clinical Gold Standard by 2012 for the Treatment of Metastatic Hormone-Refractory Prostate Cancer | Palatin Technologies Announces Extension of Research Collaboration and License Agreement with AstraZeneca | MedImmune Advances Asthma Program With Start of Phase 2 Clinical Trial for Antibody Targeting IL-5 Receptor | AstraZeneca Appoints Graham Baker Vice President and Chief Financial Officer for North America | Par Pharmaceutical Halts Shipment of Budesonide Inhalation Suspension | Par Pharmaceutical Begins Shipment of Budesonide Inhalation Suspension Immediately | AstraZeneca Appoints Rich Fante as President of its U.S. Business | MedImmune Announces Winners of Third Annual Research Abstract Competition | MedImmune Announces Zook as President | Statin Reduces Heart Attack, Stroke Rates in Patients With Normal Cholesterol but Elevated C-Reactive Protein | Pivotal Data Showed SYMBICORT(R) Improved Lung Function in Adults with COPD | MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology | AstraZeneca, Cognizant Announce a Five-Year Deal; Expand Their Global Services Partnership | Cognizant Formally Inaugurates Delivery Center in Hungary to Meet Global 2000 Clients? European Near-shore IT, BPO Needs |
 
  
Items 1-25/86 displayed. [1-25][26-50][51-75][76-86] next
SaveDateJob TitleCity CountryStateCompany NamePay
Jul 31 PET Process Facilitator - Newark
 Delaware, USA Delaware  AstraZeneca Pharmaceuticals Not specified
Jul 31 Associate Scientist /Sr. Associate Scientist- Bioscience
 Boston, USA Massachusetts  AstraZeneca Pharmaceuticals Not specified
Jul 31 Pharmaceuticals Sales Specialist - MCL - Norman; OK
 Central-Oklahoma City, USA Oklahoma  AstraZeneca Pharmaceuticals Not specified
Jul 31 Pharmaceuticals Sales Specialist - MCL - Bridgeport; CT
 Danbury/Bridgeport, USA Connecticut  AstraZeneca Pharmaceuticals Not specified
Jul 31 Pharmaceutical Sales Specialist - Hospital - Springfield; MA
 Western/Springfield, USA Massachusetts  AstraZeneca Pharmaceuticals Not specified
Jul 31 Corp Commun Mgr-Edit Proj Mgr
 Delaware, USA Delaware  AstraZeneca Pharmaceuticals Not specified
Jul 31 Pharmaceuticals Sales Specialist - MCL - San Diego S; CA
 San Diego, USA California  AstraZeneca Pharmaceuticals Not specified
Jul 31 Pharmaceuticals Sales Specialist - MCL - Pueblo; CO
 Colorado Springs/Pueblo, USA Colorado  AstraZeneca Pharmaceuticals Not specified
Jul 31 Pharmaceuticals Sales Specialist - MCL - Manhattan North; NY
 Northern, USA New York  AstraZeneca Pharmaceuticals Not specified
Jul 31 Pharmaceuticals Sales Specialist - MCL - Albuquerque NW; NM
 Albuquerque, USA New Mexico  AstraZeneca Pharmaceuticals Not specified
Jul 31 District Sales Manager - MCL - Philadelphia S; PA
 Philadelphia, USA Pennsylvania  AstraZeneca Pharmaceuticals Not specified
Jul 31 Pharmaceuticals Sales Specialist - MCL- Knoxville SW; TN
 Knoxville, USA Tennessee  AstraZeneca Pharmaceuticals Not specified
Jul 31 Pharmaceuticals Sales Specialist - MCL - Louisville E; KY
 Louisville, USA Kentucky  AstraZeneca Pharmaceuticals Not specified
Jul 31 Pharmaceutical Sales Specialist - CNS SC2 - Oakland; CA
 Oakland/East Bay, USA California  AstraZeneca Pharmaceuticals Not specified
Jul 31 District Sales Manager - MCR - Atlanta N; GA
 Atlanta North, USA Georgia  AstraZeneca Pharmaceuticals Not specified
Jul 31 Pharmaceuticals Sales Specialist - MCL - Pasadena; TX
 Houston, USA Texas  AstraZeneca Pharmaceuticals Not specified
Jul 31 Pharmaceutical Sales Specialist - CNS SC1 - Norristown; PA - FWA Job Share
 Philadelphia, USA Pennsylvania  AstraZeneca Pharmaceuticals Not specified
Jul 31 Safety Surveillance Product Manager
 Delaware, USA Delaware  AstraZeneca Pharmaceuticals Not specified
Jul 31 Pharmaceuticals Sales Specialist -MCL - Covington; LA
 New Orleans, USA Louisiana  AstraZeneca Pharmaceuticals Not specified
Jul 31 Pharmaceuticals Sales Specialist - MCL - Houston S; TX
 Houston, USA Texas  AstraZeneca Pharmaceuticals Not specified
Jul 31 Pharmaceuticals Sales Specialist - MCL - Beaumont; TX
 East/Tyler/Beaumont, USA Texas  AstraZeneca Pharmaceuticals Not specified
Jul 31 Pharmaceutical Sales Specialist - CNS SC1 - Brooklyn N; NY
 New York City, USA New York  AstraZeneca Pharmaceuticals Not specified
Jul 31 Pharmaceuticals Sales Specialist - MCR2 - Altoona; PA
 Pittsburgh, USA Pennsylvania  AstraZeneca Pharmaceuticals Not specified
Jul 31 Pharmaceutical Sales Specialist - CNS - Minneapolis S; MN
 Minneapolis, USA Minnesota  AstraZeneca Pharmaceuticals Not specified
Jul 31 District Sales Manager - MCL - Des Moines; IA
 Central/Des Moines, USA Iowa  AstraZeneca Pharmaceuticals Not specified